News

Three of the 9 patients who received the infusion demonstrated best overall response of Stable Disease, and investigators determined dose level 2 to be the biologically effective dose.

Niels van de Donk, MD, PhD, professor, Amsterdam University Medical Centers, discussed positive findings from cohort B of the CARTITUDE-2 study.

Regardless of bone marrow cellularity, bone marrow minimal residual disease (MRD) negativity at month 1 correlated with deep response and prolonged PFS.

Melissa Alsina, MD, gave a talk on novel CAR therapies, targets, and approaches at the 2022 ASCO meeting.

Findings from the US-based study align with results from a phase 1b/2 study completed in China of CT041 in patients with gastric and gastroesophageal junction adenocarcinoma.

The assistant professor of medicine at University of Pennsylvania Hospital stressed the importance of tumor sequencing.

The phase 1, open-label, single-arm study demonstrated favorable safety and robust efficacy for the autologous GPRC5D-directed CAR-T cell therapy.

Data were presented at ASCO 2021 and EHA 2021 for the initial 19 patients. Now, investigators are painting a fuller picture with an additional 9.

The BASECAMP-1 study is currently enrolling participants to explore the feasibility of manufacturing a novel CAR T-cell therapy with a target antigen activator and a HLA LOH-based blocker.

Cohort A of the CARTITUDE-2 study is evaluating cilta-cel safety and efficacy in patients with multiple myeloma who received 1 to 3 prior lines of therapy.

“Therapy was found to be safe and tolerable. This initial data formed the basis for further exploration that is currently ongoing in the IGNYTE-ESO study,” investigator Sandra P. D’Angelo, MD, tells CGTL.

The associate professor of medicine at Medical College of Wisconsin discussed advantages of the ARC-SparX platform.

High response rates were seen in patients that would not meet ZUMA-2 eligibility criteria.

No differences were found in overall survival and progression free survival across races.

Review top news and interview highlights from the week ending June 3, 2022.

A recent meta-analysis reviewed data across 146 patients in 9 clinical trials.

Relma-cel was previously approved in China in September 2021 for the treatment of B-cell non-Hodgkin lymphoma.

Beti-cel was rated a B+ for lingering questions about durability and unknown risks.

A phase 1 trial evaluated the combination in patients regardless of PD-L1 status and no differences were seen between those negative or positive.

The cofounder, president, and chief executive officer of Forge Biologics discussed the company’s approach to gene therapy manufacturing.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

BioMarin now expects to file in September 2022 instead of June.

The renowned professor from University of California Los Angeles reflected on receiving the Outstanding Achievement Award from the ASGCT.

Treated patients had significant improvements in fatigue and lymphoma symptoms.

A lower objective response rate in cohort 4 reflected a higher disease burden with a greater number of tumors.

The approval was based on data from the phase 2 ELARA clinical trial, in which a complete response of more than 65% was observed.

Stefan Braam, PhD, chief executive officer of Ncardia and Cellistic discussed the companies’ work in the cell therapy space.

RP-L301 also improved hemolysis and eliminated the need for red blood cell transfusions for up to 1year after therapy.